Raul D. Santos is Director of the Lipid Clinic of the Heart Institute (InCor) of the University of São Paulo,
Brazil. He is an associate professor of the Cardiopulmonary Disease Department at the University of
São Paulo medical school and one of the coordinators of the “Hipercol Brasil” Familial
Hypercholesterolemia (FH) Genetic Cascade Screening Program. He is also a Researcher at the
Academic Research Organization of the Hospital Israelita Albert Einstein in São Paulo. After completing
his training in cardiology Dr. Santos obtained masters and Ph.D. degrees in food science at the
University of Sao Paulo. His research interests include lipid metabolism, severe forms of genetic
dyslipidemias, especially familial hypercholesterolemia and HDL deficiency, non-alcoholic fatty liver
disease, and imaging in atherosclerosis focusing on detection of vascular calcification. He has
intensively collaborated with the Ciccarone Center for the Prevention of Heart Disease from the Johns
Hopkins University (USA), the Lipid Metabolism Laboratory of Tufts University (USA) as well as with the
INSERM, UMR-ICAN 1166, University of Pierre and Marie Curie – Paris 6; Pitié-Salpétrière University
Hospital in Paris, France. He has published more than 280 papers in peer-review journals like the
Lancet, The New England Journal of Medicine, Atherosclerosis, ATVB, Circulation, The European Heart
Journal, JACC, JACC Cardiovascular Imaging, Journal of Lipid Research, Journal of Clinical Lipidology,
Lancet Diabetes & Endocrinology and Current Opinion of Lipidology among others. Dr. Santos has
coordinated and participated in many Brazilian and International guidelines on dyslipidemia, familial
hypercholesterolemia, atherosclerosis prevention, metabolic syndrome, obesity, diabetes, and
coronary heart disease. Currently, he is one of the main investigators of the EAS-FH study collaboration
as well as the 10-country FH study. He is a former scientific director (2016-2017) of the Brazilian Society
of Cardiology (SBC), a member of the Consensus Panel on Dyslipidemias of the European
Atherosclerosis Society (EAS) and is the vice president of the Iberoamerican Familial
Hypercholesterolemia network association (IBAFHN). In addition, he is one of the associate editors of
Atherosclerosis, the Journal of Clinical Lipidology, the European Journal of Preventive Cardiology, and
Diabetes Research and Clinical Practice. He has received a lifetime membership recognition award
from the US National Lipid Association (NLA), a recognition award from the Oman Society of Lipid and
Atherosclerosis (OSLA), a Paul Dudley White International Scholar Award from the American Heart
Association (AHA), honorary membership of the Colombian Society of Cardiology and Cardiovascular
Surgery (SCCV) and a top Peer-Reviewer recognition from PUBLONS among others.

Dr. Santos declares sources of funding and relationships with the following commercial stakeholders in the healthcare sector concerning consulting, speaker and or research activities from: Abbott, Aché, Amryt, Astra Zeneca, Amgen, EMS, Esperion, GETZ Pharma, Kowa, Libbs, Merck, MSD, Novo Nordisk, Pfizer, PTC Therapeutics, Roche, Sanofi.